Solnezumab is a monoclonal antibody being researched by Eli Lilly for use as a neuroprotective agent in patients with Alzheimer's disease. The drug initially received much media coverage as a scientific breakthrough, but failed to show promising effects in phase 3 clinical trials. Solnezumab has been used safely in combination with other licensed Alzheimer's treatments, such as acetylcholine esterase inhibitors or memantine, in clinical trials. In addition to Alzheimer's disease, there are other diseases in which beta amyloid is involved, such as Down syndrome and cerebral amyloid angiopathy, for which solenezumab may be used. However, its use in these conditions has not yet been studied. No safety concerns have been identified in any of the studies conducted. Some patients experienced reactions to the drug that resolved on their own. Other adverse reactions that have occurred, such as headache or hematoma, were not considered to be related to the treatment. Some anti-beta-amyloid antibodies have caused amyloid-related imaging abnormalities, which has not occurred with solanezumab.